GlycoMark Receives More than $240,000 to Advance Blood Test for Diabetes and Pre-Diabetes

Published: Nov 05, 2010

WINSTON-SALEM, N.C.--(BUSINESS WIRE)--GlycoMark, a research and development company for diabetes testing, has been awarded $244,479 to advance the company’s innovative early detection algorithm for diabetes and pre-diabetes, which combines the hemoglobin A1c (HbA1c) and 1,5-anhydroglucitol (GlycoMark) blood tests. The company received the maximum allowable amount under the Qualifying Therapeutic Discovery Project (QTDP), part of the Patient Protection and Affordable Care Act of 2010.

Back to news